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KEY POINTS
 Point-of-care (POC) testing is a rapidly expanding area of growth for infectious diseases
due to the consolidation of clinical microbiology laboratories.
 Advances in technology have increased the quality of results available in the POC setting.
 The increasing complexity of the technology involved in POC testing requires oversight by
laboratory professionals.

Point-of-care (POC) testing can be defined as testing performed in close proximity to the
patient with results available within a timeframe that allows for an intervention to take
place while the patient is still in the care of the provider.1,2 The terms POC and near patient testing may be used interchangeably because they often refer to testing performed
using the same systems although the regulatory requirements may vary. The key
distinction may be the level of regulatory oversight based on the complexity of testing.
POC testing is often used to refer to waived testing under CLIA (Clinical Laboratory
Improvement Amendments Act) but could include more complex testing nonwaived
testing performed in the near patient setting. Traditional infectious disease–related
POC testing typically provides results in 15 to 20 minutes but even results available in
<1 hour from the time of specimen receipt are useful in patient management. There
are obvious advantages to having results available immediately for patient care:
1. A timely answer can alleviate patient anxiety and improve patient satisfaction.
2. Allows the care provider to initiate appropriate therapy immediately if needed
where empiric coverage is adequate, for example, streptococcal pharyngitis and
sexually transmitted diseases.
3. Reduces the need for follow-up visits that add to the burden on the patient and the
growing cost of health care.
4. Rapid testing results can ensure the optimal use of limited health care resources by
determining which patients need to be in isolation due to potential transmissible

Clinical Microbiology, Department of Pathology and Laboratory Medicine, Henry Ford Hospital,
2799 West Grand Boulevard, Detroit, MI 48202, USA
E-mail address: LSAMUEL2@hfhs.org
Clin Lab Med 40 (2020) 483–494
https://doi.org/10.1016/j.cll.2020.08.006
0272-2712/20/ª 2020 Elsevier Inc. All rights reserved.

labmed.theclinics.com

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com
by Elsevier on February 22, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights
reserved.

484

Samuel

pathogens and can play a significant role in interrupting community-based transmission of common pathogens, such as those causing infectious diarrhea or sexually transmitted diseases.
5. POC testing also improves the care of patients who are unlikely to return for subsequent visits. In resource-poor settings where patients have to travel long distances to obtain primary care, it is often unreasonable to expect them to return
after laboratory results become available for additional care.
Clinical microbiology diagnostic testing has traditionally centered around the use of
time-consuming methods such as viral and bacterial cultures. Bacterial cultures can
take anywhere from 1 to 14 days depending on the suspected pathogen. Cultures
for specific pathogens such as Mycobacterium tuberculosis require an incubation
period of 6 to 8 weeks for a negative result. Viral cultures can require 1 to 21 days
of incubation but have been mostly replaced by molecular-based methods. The transition from viral cultures to molecular methods has significantly improved the time to
result but these assays are often batched and performed at specialized laboratories so
that the results are not available in a timely manner.3 Non–culture-based tests, such as
stains for stool-based pathogens, require additional expertise and are not available in
the POC setting.
Clinical microbiology laboratories have historically operated on a 9-to-5 schedule
with limited services available outside routine working hours and on weekends, but
this model has changed over time with increased focus on laboratory utilization and
cost-effective strategies that facilitate timely patient care. The manual nature of microbiology testing made it less conducive to automated testing but over the years, improvements in technology have allowed for the implementation of highly automated
culture-based platforms. These systems enhance the performance of clinical microbiology laboratories in terms of efficiency, speed, and culture yield.4 The cost of these
automated systems, shortage of trained laboratory personnel, and the constant pressure to reduce health care costs have encouraged the consolidation of microbiology
laboratories into core facilities to ensure optimal utilization of these systems. Automated testing still requires prolonged culture incubation, and results are not available
during the course of the patient visit. The advantages of this integrated approach to
testing include the ability to provide expanded testing services around the clock
and improve overall laboratory performance.5 However, the consolidation of laboratory services into core facilities that are geographically distant from patient care locations and community hospitals within an expanded network can introduce further
delays in results due to transport time. The consolidated laboratory model could
also lead to batch processing of specimens due to the transport requirements but
this may be offset by the extended working hours and the access to automation,
advanced expertise, and testing panels.5 With advances in testing technology, the
time spent in transport often represents the largest source of delay for obtaining
results.6
The transition to diagnosis-based reimbursement in the 1980s was expected to
negatively impact centralized laboratory testing but the implementation of the Clinical
Laboratory Improvement Amendment 1988 (CLIA 88), discouraged the expansion of
laboratory testing into the primary care setting.6 The recent growth in POC testing
coincided with the development of novel technologies and the miniaturization of existing technologies that brought improved assay performance to the near patient setting.
The merger of clinical microbiology laboratories into core facilities coupled with the
advances in POC testing system development has led to renewed interest in the role of
near patient testing.1 Some health care institutions have implemented rapid response
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laboratories with a limited test menu composed of assays that can be performed in
less than 3 hours to supplement the capabilities of the core laboratories.7 These rapid
response laboratories provide a limited menu of tests, are typically staffed by qualified
laboratory personnel, and provide actionable timely results. This model can range
from the traditional concept of POC testing, which is performed by the providers in
the patient care setting, to more complex molecular testing and limited processing
of positive blood cultures.
The term POC encompasses tests using a broad range of technologies. These
include
1. Direct detection of antigen: This relates to the capture of antigen using a specific
antibody and the detection of this antigen-antibody complex typically using a
lateral flow assay or a variant of this technology, for example, rapid influenza or
group A streptococcal antigen testing.
2. Detection of antibody: These are fingerstick assays for the detection of antibody
toward specific pathogens, for example, human immunodeficiency virus (HIV).
3. Direct detection of pathogen RNA/DNA: Current nucleic acid amplification technologies (NAAT)-based testing directly detects the presence of pathogen genomic
material in the patient sample, for example, polymerase chain reaction (PCR)based detection of influenza and group A streptococci in respiratory samples.
POC testing has traditionally operated under the premise that speed and ease of
use are essential but this is often achieved at the cost of reduced sensitivity and/or
specificity. The regulatory framework for POC testing is described later in this document, but for this reason, POC testing has often been limited to settings in which
the impact of an errant result is limited or can be mitigated by reflex testing. Clinical
microbiologists have tended to question the potential for POC testing because of
the inherent performance-related issues. Until recently, a significant proportion of
POC testing was limited to lateral flow assays for common respiratory pathogens,
such as group A streptococci, influenza, and respiratory syncytial virus (RSV), but performance limitations meant that negative results often had to be confirmed by alternative molecular or culture-based methods. Nevertheless, POC testing can play an
important role in the diagnostic algorithm.
 Rapid streptococcal antigen testing allows quick determination and treatment of
a common pathogen that can have significant long-term implications for patient
health. However, because the sensitivity of the streptococcal antigen tests are
only approximately 86%, negative streptococcal antigen results should be
confirmed by traditional culture-based or molecular testing, particularly in
children.8,9
 For the detection of sexually transmitted pathogens, such as Trichomonas,
provider-performed microscopy was the mainstay of diagnostic testing but the
sensitivity of this approach was extremely limited and relied on timely specimen
transport and immediate processing as well as expertise in microscopy. The
development of Trichomonas antigen-based testing allowed for not just significantly improved sensitivity over microscopy-based methods but also reduced
the labor and expertise required for testing. In spite of these improvements,
POC testing for Trichomonas does not rule out infection and negative results
need to be confirmed by molecular methods if clinical suspicion persists.10
 POC testing for M tuberculosis has the potential to significantly impact both patient
care and appropriate utilization of institutional resources. In low tuberculosis (TB)
incidence countries, 1 to 2 negative TB PCR results can be used to remove
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patients from airborne isolation with significant cost savings.11 In other settings, a
rapid TB PCR result can be used to not just to establish a diagnosis but detect the
presence of resistance markers in patients who have traveled long distances to
obtain care and are unlikely to return for follow-up with traditional methods for
diagnosis of M tuberculosis, such as culture, which can take 6 to 8 weeks to obtain
a final result.12 The utility of POC testing in this setting is challenged by the costs
and logistical challenges of maintaining expensive PCR-based reagents and
equipment in resource-poor settings. In high disease prevalence settings, it may
not be cost-effective to rely on expensive molecular-based POC testing.13
 Rapid HIV testing has become the mainstay of public health efforts to combat the
spread of HIV especially among populations that do not routinely access health
care services; these are antibody-based tests that are useful under these circumstances but both positive and negative results should be confirmed in high-risk
individuals.14
Negative POC antigen-based testing results for most pathogens have limited value
in actual patient care due to inadequate sensitivity. Negative results typically represent
the vast majority of results and many institutions were routinely confirming negative
influenza and RSV antigen results by alternative methods.15 Recently the Food and
Drug Administration (FDA) acknowledged the limitations of POC antigen-based testing
for influenza and raised the bar for minimum performance standards for influenza antigen testing.16 This led to the development of fluorescent immunoassays that
detected the antigen using automated readers and fluorescent markers that improved
performance.17 The sensitivity of these improved assays still fell short of being able to
rule out infection and it remained common for laboratories to continue to confirm
negative results using alternative methods.17
Molecular testing or NAAT for infectious disease pathogens offer the advantages of
improved sensitivity and specificity over antigen testing. Until recently, technologies
such as real-time PCR required the use of significant training and specialized equipment. The challenges associated with use of NAAT include the need for molecular
expertise, expensive equipment/reagents, designated testing areas, and the risk of
contamination. Testing is often performed in large batches to conserve reagents
and reduce costs. Traditional molecular tests were typically not performed in the
near patient setting and were not available within a timeframe that allowed for intervention during the patient visit.
REGULATORY FRAMEWORK FOR POINT-OF-CARE TESTING

A number of factors are involved in determination of which tests are appropriate for
use in the POC setting.
CLIA 88 governs the classification of testing based on complexity. The level of
complexity is determined by the following questions18
1. How the test may be used and in which setting?
2. Who can perform the test?
3. What kind of proficiency testing and quality assurance is required?
In addition, the type of testing performed by a laboratory determines the level of regulatory oversight of the performing laboratory.
Three categories of test complexity have been established:
1. Waived
2. Moderate complexity, including provider-performed microscopy (PPM)
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3. High complexity.
In the United States, CLIA 88 outlines the different levels of complexity for testing
but it is the FDA that issues guidelines on how to interpret CLIA 88 and determines
how to categorize a new test in terms of complexity.
Waived tests generally meet the following criteria:
 The technology involved must be simple enough to have an extremely low likelihood of inaccurate results
 Should not require processing of specimens before testing
 Relatively low risk of harm to patients if the test is incorrectly performed
Nonwaived testing refers to moderate or high complexity testing. Laboratories that
perform nonwaived testing must hold a CLIA certificate as well as undergo routine inspections and follow a prescribed system of proficiency testing, quality assurance,
and personnel requirements. Sites performing waived testing on the other hand only
need a CLIA certificate and to follow manufacturer’s instructions, although they may
be subject to inspections. This makes the use of CLIA-waived testing an attractive
prospect to sites that have limited laboratory capability, resources, or access to
trained laboratory personnel ,but still want to offer some onsite testing capability for
patients with relatively minor health issues. As of March 2020, there were 193,474 sites
with CLIA-waived registration.18 POC testing may be performed under the CLIA waiver
by nonlaboratory personnel or by laboratory personnel in near patient settings such as
stat laboratories.
TRENDS IN POINT-OF-CARE TESTING

There is also renewed interest in using POC testing in nontraditional settings. The entry
of giants in the field of information technology, retail, and pharmacy into the health
care space has accelerated the transition in the capability and accessibility of POC
testing. Traditional patient care requires the patient to take time out their daily
schedule to travel to a dedicated health care facility where they spend a significant
amount of time working their way through often inefficient processes to receive care
for what are often relatively minor issues or concerns at relatively high costs. These
visits are often associated with significant costs and loss of productivity. The entities
looking to disrupt this process are seeking to provide patient care outside the confines
of traditional health care spaces; the goal being to provide some level of primary care
with minimal disruption by bringing care to the patient while they go through their daily
routine. Large corporations like Walmart already have the stated goal of bringing
low-cost primary care clinics within 15 minutes of 90% of the US population.19 The
effectiveness of these primary care clinics, which are typically staffed by nurse practitioners, hinges on the availability of infectious and noninfectious POC testing.
By integrating care into existing retail and other nontraditional spaces, providers can
offer an attractive alternative to patients and achieve efficient delivery of health care.
The challenges to this model are the need for trained personnel and the need for a new
approach to POC testing. For POC testing to have a meaningful impact, it is necessary
for the test to be relatively easy to perform even by a nonlaboratorian and for the results to be accurate enough to be actionable for the care provider without the need for
confirmation.
The volume of POC testing is expected to grow 10% to 15% annually.20 According
to the National Community Pharmacists Association (NCPA), “Point-of-care testing
provides an excellent opportunity for community pharmacies to enhance revenue
by expanding patient care services while improving health at the patient and
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population levels.”21 According to Deloitte,22 POC testing is on track to exceed immunizations as a source of revenue for the pharmaceutical retail industry. The top 4 primary opportunities for growth in POC testing as identified by the NCPA are all for
infectious disease–related assays including influenza, streptococcal antigen, HIV,
and hepatitis C detection assays.21 The volume of POC testing is growing rapidly globally at with the market expected to be valued at $3 billion annually by 2021.22
The provision of care has moved toward telehealth due to the pandemic, but is
limited by the lack of access to laboratory test results.23 The natural progression of
POC testing is therefore toward its use in at-home testing. Studies have shown that
when given the choice, patients prefer at-home testing.24 During the SARS-COV-2
outbreak, the FDA authorized the first at-home collection kit for the detection of the
virus from saliva.25 Further advances in technology are required to improve the quality
and performance of at-home POC testing with a focus toward reducing the likelihood
of errors and automated result interpretation.
It is important to note that the waived classification does not mean that the test is error
proof and not all POC testing is able to obtain the waived classification. Early POC
testing was limited to lateral flow-based antigen tests with visual detection of the positive signal by the user. These assays suffered from limited performance characteristics
with sensitivities ranging from 10%-80% in comparisons with viral culture or real-time
PCR.26 Concerns about the about the poor negative predictive value of antigenbased assays in particular for influenza prompted the FDA to reclassify rapid influenza
antigen devices as class II devices with the expectation of improved performance characteristics.16 These were then replaced by FIA-based antigen detection assays. The
performance of these FIA assays for the detection of influenza was significantly
improved over traditional antigen-based testing with sensitivity of approximately 80%
in multiple studies.17,27 These assays still fell short of real-time PCR in terms of being
able to rule out influenza. In contrast to lateral flow devices, the throughput of these
immunofluorescent-based assays was also limited by the number of instruments/
readers available with each instrument able to read one patient sample at a time.
Advances in NAAT-based testing allowed for the development of the first CLIAwaived NAAT test for influenza (Abbott ID Now, initially developed as the Alere I).27
The use of isothermal amplification–based technology eliminated the need for hardware that had the temperature cycling capabilities required for real-time PCR. This
development was a revolutionary step forward in being the first time that any molecular amplification–based technology was available to be performed at the level of primary care without the need to follow the CLIA requirements for moderate or high
complexity testing. Subsequently additional NAAT-based platforms obtained CLIA
waivers for POC testing including (among others) the Roche Liat and the Cepheid
GeneXpert, both of which use real-time PCR and are capable of detecting influenza
A, B, and RSV as well as group A streptococci using a variety of CLIA-waived assays.
The Liat can provide results for influenza A and B as well as RSV from a respiratory
sample within 22 minutes. The GeneXpert is able to provide similar results in 30 minutes with minimal sample handling requirements for both platforms. Even more revolutionary was the approval of the Biofire Filmarray Respiratory Panel EZ, which is a
multiplex panel for 14 different respiratory pathogens.
IMPACT OF POINT-OF-CARE TESTING

The ability to offer panel-based syndromic testing in the POC setting can appear to be
attractive to the clinician, but it is unclear whether there is a significant benefit associated with the detection of viral pathogens in the outpatient setting, especially
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when there are no interventions associated with some of the positive targets. The
value of these syndromic panels has been difficult to demonstrate even in the inpatient
setting and the primary care providers might also struggle to interpret panel results
that detect multiple targets although in some settings.28–30 The ResPOC trial evaluated the impact of syndromic panel-based testing in the POC testing and found
that the results reduced length of stay (LOS) and improved influenza detection and
appropriate antiviral use although it did not reduce antibiotic use.28 It is possible
that similar gains could be achieved using NAAT-based assays targeted at specific
pathogens, such as influenza alone. Mercuro and colleagues29 demonstrated that
inhouse testing using syndromic respiratory panels did not have any impact on
LOS, duration of therapy, or frequency of drug-related interventions. When appropriately used, NAAT-based POC testing can significantly impact patient care. POC group
A streptococcal NAAT-based testing was able to significantly improve appropriate
antibiotic use (97.1% vs 87.5%; P 5 .0065) when compared with an antigen-based
test.31 Implementation of an NAAT-based rapid influenza assay reduce in appropriate
antiviral use, improved appropriate antibiotic utilization, reduced LOS and also
reduced the likelihood of admission when compared with antigen-based testing.32
These findings are crucial to the adoption of NAAT-based POC technology because
of the significant capital and reagent costs that may be involved with NAAT tests,
whereas antigen-based testing does not typically require resources beyond the
testing kits and specimen collection materials. It is important for laboratories to
demonstrate the direct impact and cost savings in terms of patient care that accrue
from the adoption of these technologies. It is also essential to liaison with care providers to improve understanding of assay performance and interpretation of results.
This is necessary to ensure that changes in testing platforms translate to changes in
patient care. NAAT-based influenza and group A Streptococcal testing can offer
greater than 99% sensitivity and specificity allowing the care provider to make decisions on patient care with confidence as compared with antigen tests with limited performance characteristics. There is little doubt that POC and near patient testing is an
area of rapid growth. The continued consolidation of laboratories, the challenges with
hiring laboratory personnel and the continued development of novel POC platforms
and technologies suggests these trends will continue.
OVERSIGHT AND PERFORMANCE OF POINT-OF-CARE TESTING

The performance of NAAT-based platforms represented a significant improvement
over the previous iterations of antigen-based tests, both lateral flow and
immunofluorescent-based assays.27 However it does raise concerns about appropriate oversight of testing systems and methods that are far more complex than traditional POC-based testing. Laboratories that perform moderate and high-complexity
NAAT testing are required by their accrediting bodies to adhere to rigorous standards
and quality control.33 This includes routine use of control material, monitoring of test
statistics and assay performance and environmental sampling to detect potential
contamination. The exquisite sensitivity of NAAT-based testing means that failure to
adhere to these practices can result in erroneous results and patient harm.34 Although
NAAT-based testing in the POC setting has the potential to significantly impact patient
care, there are significant concerns that in the absence of adequate laboratory-based
oversight, problems could develop and continue undetected for significant periods of
time. In an ideal world, POC testing would be performed by appropriately trained and
qualified laboratory personnel but the current shortage of technologists ensures that is
not a realistic goal.
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A number of questions need to be addressed when moving POC testing using highly
complex testing out of the laboratory and into settings in which the users are health
care professionals who are not familiar with the challenges of NAAT testing.35 A colloquium convened by the American Academy of Microbiology recognized the need
for near patient and POC infectious disease testing but also strongly recommended
that oversight of the quality assurance processes associated with this testing should
remain under appropriate laboratory-based personnel.36
Examples of situations that demonstrate the need for laboratory oversight of POC
and near patient testing systems are not uncommon:
 Invalid results associated with influenza B–positive samples using the Roche Liat
system that generated unusual PCR curves that was determined to be related issues with the system software.37
 Point mutations in the M gene of influenza that caused false negative results using the Cepheid GeneXpert.38
 Engelmann and colleagues39 suggested there was a need to review PCR curves
under specific circumstances when using the Cepheid GeneXpert platform.
 The Abbott ID NOW was demonstrated to have lower sensitivity that other NAATbased platforms in direct comparison of sensitivity for the detection of influenza
due to the dilution effect of transport media.27
 Random sampling of the Roche Liat instrument in a testing laboratory determined that target viral RNA could be detected on the surface of and within the
instrument testing chamber. Studies eventually demonstrated that the risk of
contamination was low even in the presence of environmental contamination
with viral genomic material.40 Nevertheless, these findings reinforce the need
for rigorous adherence to protocol and regular monitoring of test results and statistics to rule out contamination.
 False positive Campylobacter and Cryptosporidium results in Biofire gastrointestinal panel testing of stool samples.41
 False positive Streptococcus pneumoniae results associated with use of the Biofire ME meningitis panel.42
Although the Biofire ME and gastrointestinal panels are not CLIA-waived POC tests,
they are often performed in the near patient setting. These quality issues were not
limited to NAAT-based testing; false positive results were identified in comparison
studies of the Quidel Quickvue Influenza A 1 B antigen test with NAAT-based testing
during the 2009 H1N1 Influenza outbreak.43
POINT-OF-CARE TESTING IN THE CORONAVIRUS DISEASE 2019 ERA

During the course of the Coronavirus Disease 2019 (COVID-19) pandemic, the
shortage of testing resources and the need for near patient testing became severe
enough that the FDA relented and relaxed the rules governing the Emergency Use
Authorization (EUA) process to allow for expedited approval of testing platforms.44
One of the first POC testing platforms to receive approval to operate under a CLIA
waiver certificate was the Abbott ID NOW using isothermal amplification.45 Early results were promising, but as was the case with the Abbott ID Now Influenza assay, issues that could impact the sensitivity of the assay were identified.46 Subsequently, the
FDA also issued a notification that negative results may require confirmation by an
alternative NAAT-based assay.47 Other NAAT-based platforms using real-time PCR
that are capable of being used in the POC space are either now available or in development. This includes multiplex and syndromic panels that incorporate SARS-COV-2
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detection along with other respiratory viral pathogens. These combinations may prove
essential during the flu season when multiple pathogens are circulating in the community and could potentially cause coinfections.48
In the antibody testing space, under the EUA authorization, numerous vendors were
allowed to market POC antibody detection assays for COVID-19 with the disclaimer
that these assays were not intended for diagnostic use.49 Despite these restrictions,
the market was flooded with numerous POC antibody assays with few data on actual
performance characteristics. These assays were widely available and being used
inappropriately for diagnosis despite the limitations.50 Responding the reports
regarding inappropriate use and substandard performance of the these POC antibody
tests, the FDA requested the manufacturers to provide additional information on assay
performance characteristics and eventually took action to remove those that did not
comply or meet minimum standards.51
Despite the performance issues associated with early iterations of POC tests for
COVID-19, the need for rapid near patient testing is essential to the management
of this outbreak. The pandemic has forced health care providers to consider innovative steps to provide primary care without having potentially infectious patients
congregating in close proximity with high-risk individuals. Providers are increasingly
relying on telemedicine to continue to provide care to the patient remotely.52 However, the extent of care is limited by the ability to obtain laboratory test results.
The FDA recently approved the first at-home collection kit for testing for
COVID-19 in saliva but these assays are not widely available.53 Subsequent data
on the performance of saliva for the detection of COVID-19 has not been consistent
and it remains to be determined whether this sample type will be widely adopted.
Specimen collection for COVID-19 remains challenging with collection of the
preferred specimen type; nasopharyngeal swabs requiring specific training and
infection control precautions to minimize risk to the individual collecting specimens.
Approval of alternative specimen types such as nasal swabs, sputum, and tracheal
aspirates have eased these concerns, although challenges still remain in the availability of swabs and transport media.
SUMMARY

Technological advances have ensured that POC testing can become central to patient
care and management. Further studies are necessary to determine the optimal strategies to use these platforms in a partnership between laboratories and care providers.
The increasing complexity of these testing systems makes it essential that laboratory
personnel are involved in the oversight of POC testing systems and platforms.
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